Abstract | BACKGROUND: OBJECTIVE: METHODS: This 24-week, open-label, controlled trial was conducted at the Division of Endocrinology and Metabolism, Veterans Affairs Medical Center (Phoenix, Arizona). Study participants were aged 32 to 75 years and had recent-onset (established by a short duration of symptoms 6 weeks to 6 months prior to the study) type 2 DM, or were age-matched healthy volunteers (control group). In the diabetic patients, glimepiride tablets were administered orally, initially at 2 mg once daily in the morning, with the dosage increased by 1 mg every 2 weeks until fasting plasma glucose (FPG) decreased to 6.7 mmol/L; the dosage was then maintained for the remainder of the 24-week study period. Oral glucose tolerance tests (OGTTs) were conducted in the control group and before treatment and at 24 weeks after the achievement and maintenance of glycemic control ( glycosylated hemoglobin <7.0%) in the diabetic group. For OGTT, plasma insulin and glucose levels were determined after the subjects fasted overnight and then at every 15 minutes for 2 hours after glucose challenge. RESULTS: Fourteen diabetic men (mean [SEM] age, 50 [6] years; range, 32-75 years) and 10 male healthy controls (mean [SD] age, 48 [5] years; range, 30-68 years) were enrolled. In the DM group, FPG decreased significantly after treatment ( P<0.001); fasting plasma insulin was markedly elevated before treatment (P<0.001 vs controls) and decreased after treatment ( P<0.01) but did not normalize; first-phase insulin secretion was markedly inhibited before treatment ( P<0.001 vs controls) and normalized after treatment ( P<0.001) total insulin secretion significantly improved after treatment ( P<0.01) but did not normalize. Finally, the pretreatment insulin sensitivity index decreased significantly (P<0.01) after treatment and normalized in 6 of 14 patients (42.9%) with type 2 DM. CONCLUSIONS: In this study, glimepiride achieved desirable glycemic control in patients with recent-onset type 2 DM through improvement in insulin secretion and sensitivity.
|
Authors | Mary U Kabadi, Udaya M Kabadi |
Journal | Clinical therapeutics
(Clin Ther)
Vol. 26
Issue 1
Pg. 63-9
(Jan 2004)
ISSN: 0149-2918 [Print] United States |
PMID | 14996518
(Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Hypoglycemic Agents
- Insulin
- Sulfonylurea Compounds
- glimepiride
|
Topics |
- Adult
- Aged
- Diabetes Mellitus, Type 2
(drug therapy)
- Glucose Tolerance Test
- Humans
- Hypoglycemic Agents
(pharmacology, therapeutic use)
- Insulin
(agonists, blood, metabolism)
- Insulin Resistance
- Insulin Secretion
- Male
- Middle Aged
- Sulfonylurea Compounds
(pharmacology, therapeutic use)
|